Spectral-domain optical coherence tomography as an indicator of fluorescein angiography leakage from choroidal neovascularization

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 8, 2011, Pages 5579-5586

  Giani, Andrea ^a,b   Luiselli, Cristiano ^b   Esmaili, Daniel D ^a   Salvetti, Paola ^b   Cigada, Mario ^b   Miller, Joan W ^a   Staurenghi, Giovanni ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

AGED; ARTICLE; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; CONTRAST MEDIUM EXTRAVASATION; METABOLISM; METHODOLOGY; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PATHOPHYSIOLOGY; RETINA; RETINA BLOOD VESSEL;

AGED; AGED, 80 AND OVER; CHOROIDAL NEOVASCULARIZATION; CROSS-SECTIONAL STUDIES; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; RETINA; RETINAL VESSELS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 80053330758     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6617     Document Type: Article

References (28)

1. Attebo K, Mitchell P, Smith W. Visual acuity and the causes of visual loss in Australia. The Blue Mountains Eye Study. Ophthalmology. 1996;103:357-364.
2. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of agerelated macular degeneration in the United States. Arch Ophthalmol. 2004;122:564-572.
3. Macular Photocoagulation Study Group. Laser-photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol. 1991;109:1232-1241.
4. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Arch Ophthalmol. 1999;117:1329-1345.
5. Blinder KJ, Bradley S, Bressler NM, et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol. 2003;136:407-418.
6. Miller JW, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol. 1999;117:1161-1173.
7. Huang D, Swanson EA, Lin CP, et al. Optical coherence tomography. Science. 1991;254:1178-1181.
8. Menke MN, Dabov S, Sturm V. Features of age-related macular degeneration assessed with three-dimensional Fourier-domain optical coherence tomography. Br J Ophthalmol. 2008;92:1492-1497.
9. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355: 1419-1431.
10. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
11. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148:43-58. e1.
12. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol. 2010;94:2-13.
13. Schuman SG, Koreishi AF, Farsiu S, Jung SH, Izatt JA, Toth CA. Photoreceptor layer thinning over drusen in eyes with age-related macular degeneration imaged in vivo with spectral-domain optical coherence tomography. Ophthalmology. 2009;116: 488-496. e2.
14. Hee MR, Baumal CR, Puliafito CA, et al. Optical coherence tomography of age-related macular degeneration and choroidal neovascularization. Ophthalmology. 1996;103:1260-1270.
15. Barbazetto I, Burdan A, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment: TAP and VIP report no. 2. Arch Ophthalmol. 2003;121:1253-1268.
16. VanNewkirk MR, Weih L, McCarty CA, Stanislavsky YL, Keeffe JE, Taylor HR. Visual impairment and eye diseases in elderly institutionalized Australians. Ophthalmology. 2000;107:2203-2208.
17. Khurana RN, Dupas B, Bressler NM. Agreement of time-domain and spectral-domain optical coherence tomography with fluorescein leakage from choroidal neovascularization. Ophthalmology. 2010;117:1376-1380.
18. Coscas F, Coscas G, Souied E, Tick S, Soubrane G. Optical coherence tomography identification of occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2007;144:592-599.
19. Liakopoulos S, Ongchin S, Bansal A, et al. Quantitative optical coherence tomography findings in various subtypes of neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49:5048-5054.
20. Zweifel SA, Engelbert M, Laud K, Margolis R, Spaide RF, Freund KB. Outer retinal tubulation: a novel optical coherence tomography finding. Arch Ophthalmol. 2009;127:1596-1602.
21. Wojtkowski M, Leitgeb R, Kowalczyk A, Bajraszewski T, Fercher AF. In vivo human retinal imaging by Fourier domain optical coherence tomography. J Biomed Opt. 2002;7:457-463.
22. Ahlers C, Geitzenauer W, Stock G, Golbaz I, Schmidt-Erfurth U, Prunte C. Alterations of intraretinal layers in acute central serous chorioretinopathy. Acta Ophthalmol. 2009;87:511-516.
23. Bolz M, Schmidt-Erfurth U, Deak G, Mylonas G, Kriechbaum K, Scholda C. Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology. 2009;116:914-920.
24. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res. 2001;20:705-732.
25. Chen W, Stambolian D, Edwards AO, et al. Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. Proc Natl Acad Sci USA. 2010;107:7401-7406.
26. Penfold PL, Madigan MC, Gillies MC, Provis JM. Immunological and aetiological aspects of macular degeneration. Prog Retin Eye Res. 2001;20:385-414.
27. Izumi-Nagai K, Nagai N, Ohgami K, et al. Inhibition of choroidal neovascularization with an anti-inflammatory carotenoid astaxanthin. Invest Ophthalmol Vis Sci. 2008;49:1679-1685.
28. Holz FG, Jorzik J, Schutt F, Flach U, Unnebrink K. Agreement among ophthalmologists in evaluating fluorescein angiograms in patients with neovascular age-related macular degeneration for photodynamic therapy eligibility (FLAP-study). Ophthalmology. 2003;110:400-405.